SCHEMBL19087043

SCHEMBL19087043

COC(=O)c1ccccc1Cn1cc(C)cn1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.53
LMNA P02545 2/20 0.53
KDM4E B2RXH2 2/20 0.53
HSD17B10 Q99714 1/20 0.53
NPBWR1 P48145 1/20 0.47
MYC P01106 1/20 0.44
CYP1A2 P05177 1/20 0.44
POLB P06746 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2C19 P33261 1/20 0.44
MAPT P10636 1/20 0.44
KLKB1 P03952 3/20 0.44
HIF1A Q16665 1/20 0.43
AGTR1 P30556 1/20 0.43
AGTR2 P50052 1/20 0.43
MEN1 O00255 1/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
KMT2A Q03164 1/20 0.42
SIRT1 Q96EB6 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19087045 0.85 ALDH1A1 (0.44) ALDH1A1LMNAKDM4EMYCPOLB
SCHEMBL27286149 0.84 LMNA (0.48) ALDH1A1LMNAKDM4EHSD17B10NPBWR1
SCHEMBL27376022 0.84 L3MBTL1 (0.47) ALDH1A1LMNAKDM4ENPBWR1CYP1A2
SCHEMBL19077852 0.84 NPBWR1 (0.46) ALDH1A1LMNAKDM4EHSD17B10NPBWR1
SCHEMBL27378931 0.80 NPBWR1 (0.43) ALDH1A1LMNAKDM4EHSD17B10NPBWR1
SCHEMBL30736732 0.78 NPBWR1 (0.41) ALDH1A1LMNAKDM4ENPBWR1CYP1A2
SCHEMBL6782969 0.75 TSHR (0.49) ALDH1A1LMNAKDM4EHSD17B10MAPT
SCHEMBL17221323 0.75 KLKB1 (0.56) ALDH1A1LMNAKDM4EHSD17B10KLKB1
SCHEMBL19158354 0.75 ALDH1A1 (0.49) ALDH1A1KDM4EHSD17B10POLBMAPT
SCHEMBL19086984 0.74 CD74 (0.57) KDM4EPOLBMAPTKLKB1TAS2R8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3792256-A1 PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS Incyte Corporation (US) 2021-03-17 EP disclosed
EP-3400221-B1 PYRAZOL / IMIDAZOL SUBSTITUTED PYRIDINES AS PI3K-GAMMA INHIBITORS INCYTE CORP (US) 2020-08-26 EP disclosed
WO-2017120194-A1 PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS INCYTE CORPORATION (US) 2017-07-13 WO disclosed
US-20170190689-A1 PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS INCYTE CORPORATION 2017-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170190689-A1 PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS PIK3CG, PIK3CD, PIK3CB ALDH1A1 2997/4885LMNA 3680/4885KDM4E 2506/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.